• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

正电子发射断层扫描/计算机断层扫描技术研究阳离子宿主防御肽 LL-37 的生物分布

Biodistribution of the cationic host defense peptide LL-37 using SPECT/CT.

机构信息

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada.

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada; Department of Physics and Astronomy, Faculty of Science, University of British Columbia, Vancouver, Canada.

出版信息

Eur J Pharm Biopharm. 2024 Sep;202:114398. doi: 10.1016/j.ejpb.2024.114398. Epub 2024 Jul 5.

DOI:10.1016/j.ejpb.2024.114398
PMID:38972467
Abstract

Human cathelicidin LL-37, a cationic host defense peptide (CHDP), has several important physiological roles, including antimicrobial activity, immune modulation, and wound healing, and is a being investigated as a therapeutic candidate for several indications. While the effects of endogenously produced LL-37 are well studied, the biodistribution of exogenously administered LL-37 are less known. Here we assess the biodistribution of a gallium-67 labeled variant of LL-37 using nuclear imaging techniques over a 48 h period in healthy mice. When administered as an intravenous bolus just over 20 µg, the LL-37-based radiotracer was rapidly cleared from the blood, largely by the liver, while an appreciable fraction of the dose temporarily distributed to the lungs. When administered subcutaneously at the same dose level, the radiotracer was absorbed systemically following a two-phase kinetic model and was predominately cleared renally. Uptake into sites rich in immune cells, such as the lymph nodes and the spleen, was observed for both routes of administration. Scans of free gallium-67 were also performed as controls. Important preclinical insights into the biodistribution of exogenously administered LL-37 were gained from this study, which can aid in the understanding of this and related cationic host-defense peptides.

摘要

人源杀菌肽 LL-37 是一种阳离子宿主防御肽 (CHDP),具有多种重要的生理作用,包括抗菌活性、免疫调节和伤口愈合,目前正在作为多种适应症的治疗候选药物进行研究。虽然内源性产生的 LL-37 的作用已经得到了很好的研究,但外源性给予的 LL-37 的生物分布知之甚少。在这里,我们使用核成像技术在健康小鼠中评估了一种放射性标记的 LL-37 变体在 48 小时内的生物分布。当作为静脉内推注给予略高于 20μg 的剂量时,基于 LL-37 的放射性示踪剂很快从血液中清除,主要通过肝脏,而相当一部分剂量暂时分布到肺部。当以相同的剂量水平皮下给予时,放射性示踪剂在体内通过两阶段动力学模型被吸收,并主要通过肾脏清除。两种给药途径都观察到放射性示踪剂在富含免疫细胞的部位(如淋巴结和脾脏)的摄取。还进行了游离镓 67 的扫描作为对照。本研究获得了对外源性给予的 LL-37 的生物分布的重要临床前见解,这有助于理解这种和相关的阳离子宿主防御肽。

相似文献

1
Biodistribution of the cationic host defense peptide LL-37 using SPECT/CT.正电子发射断层扫描/计算机断层扫描技术研究阳离子宿主防御肽 LL-37 的生物分布
Eur J Pharm Biopharm. 2024 Sep;202:114398. doi: 10.1016/j.ejpb.2024.114398. Epub 2024 Jul 5.
2
Biodistribution of Native and Nanoformulated Innate Defense Regulator Peptide 1002.天然和纳米配方固有防御调节剂肽 1002 的生物分布。
Mol Pharm. 2024 Jun 3;21(6):2751-2766. doi: 10.1021/acs.molpharmaceut.3c01169. Epub 2024 May 1.
3
Biodistribution and toxicity of innate defense regulator 1018 (IDR-1018).先天防御调节剂 1018(IDR-1018)的生物分布和毒性。
Eur J Pharm Biopharm. 2022 Oct;179:11-25. doi: 10.1016/j.ejpb.2022.08.004. Epub 2022 Aug 24.
4
Preparation, radiolabeling with Tc and Ga and biodistribution studies of albumin nanoparticles covered with polymers.聚合物覆盖的白蛋白纳米颗粒的制备、Tc 和 Ga 标记及生物分布研究。
Rev Esp Med Nucl Imagen Mol (Engl Ed). 2020 Jul-Aug;39(4):225-232. doi: 10.1016/j.remn.2020.02.002. Epub 2020 Mar 20.
5
Unique features of human cathelicidin LL-37.人源杀菌肽LL-37的独特特征。
Biofactors. 2015 Sep-Oct;41(5):289-300. doi: 10.1002/biof.1225. Epub 2015 Oct 5.
6
Transient cutaneous adenoviral gene therapy with human host defense peptide hCAP-18/LL-37 is effective for the treatment of burn wound infections.用人宿主防御肽hCAP-18/LL-37进行短暂性皮肤腺病毒基因治疗对烧伤创面感染有效。
Gene Ther. 2005 Oct;12(20):1494-502. doi: 10.1038/sj.gt.3302568.
7
Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37.人源抗菌肽 LL-37 诱导的抗病毒活性和增强的宿主对流感感染的防御。
PLoS One. 2011;6(10):e25333. doi: 10.1371/journal.pone.0025333. Epub 2011 Oct 21.
8
High-quality 3D structures shine light on antibacterial, anti-biofilm and antiviral activities of human cathelicidin LL-37 and its fragments.高质量的3D结构揭示了人源抗菌肽LL-37及其片段的抗菌、抗生物膜和抗病毒活性。
Biochim Biophys Acta. 2014 Sep;1838(9):2160-72. doi: 10.1016/j.bbamem.2014.01.016. Epub 2014 Jan 23.
9
Emerging roles of the host defense peptide LL-37 in human cancer and its potential therapeutic applications.宿主防御肽 LL-37 在人类癌症中的新兴作用及其潜在的治疗应用。
Int J Cancer. 2010 Oct 15;127(8):1741-7. doi: 10.1002/ijc.25489.
10
Differential regulation of human cathelicidin LL-37 by free fatty acids and their analogs.游离脂肪酸及其类似物对人源抗菌肽 LL-37 的差异调控。
Peptides. 2013 Dec;50:129-38. doi: 10.1016/j.peptides.2013.10.008. Epub 2013 Oct 18.

引用本文的文献

1
Genetically Modified Mesenchymal Stromal/Stem Cells as a Delivery Platform for SE-33, a Cathelicidin LL-37 Analogue: Preclinical Pharmacokinetics and Tissue Distribution in C57BL/6 Mice.基因工程改造的间充质基质/干细胞作为抗菌肽LL-37类似物SE-33的递送平台:C57BL/6小鼠的临床前药代动力学和组织分布
Antibiotics (Basel). 2025 Apr 24;14(5):429. doi: 10.3390/antibiotics14050429.